Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
To learn how women and underrepresented groups can secure seats on boards of directors, BioSpace spoke with perception analyst Dian Griesel and board member Terry Coelho.
Mid-July is a relatively quiet time for the FDA in terms of drug approvals, but Incyte and Arcutis will have all eyes on the regulator as they await decisions in vitiligo and psoriasis.
MacroGenics’ Phase II trial shuts down after a patient death believed to be related to enoblituzumab combo, while Exelixis’ Cabometyx combo improves PFS in renal cell carcinoma.
Roche had a good week, sharing positive data from Genentech’s study on Vabysmo for age-related macular degeneration and its breast cancer combination therapy, Perjeta.
Discover the biggest barriers patients face when seeking healthcare treatment, and find out what physicians can do to help patients overcome these barriers and improve patient engagement.
Researchers point out that antibodies against amyloid are still considered an essential approach to treating Alzheimer’s, but the leading risk factor for sporadic AD is aging.
As a result of this new data, the company “has improved the statistical analysis of the ALLOB Phase IIb study.” The changes should speed up the overall recruitment and study.
Omega Therapeutics announced Thursday that the Investigational New Drug (IND) application for its hepatocellular carcinoma (HCC) candidate OTX-2002 has been granted by the FDA.
Unnamed sources “familiar with the matter” informed Bloomberg that CStone’s leadership team is working with Goldman Sachs to determine if there are interested buyers.
Once proven clinically safe and effective, MIT’s technology could pave the way toward “self-boosting” vaccines and eliminate the need for multiple shots.
Recent advances in precision medicine and genomics have launched an explosion in immunotherapies that are resulting in real cures and earlier diagnoses - and more healthy years for individuals.
New leaders and top executive roles were selected to guide biopharma and life science companies from Apertura Gene Therapy to CytoDyn, Vaccentis AG, Suvoda LLC, IN8bio and more.
